Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2569669 | 1.00 | CNR2 (0.54) | CNR2CYP2C8CYP2D6CNR1CYP2C19 | |
| SCHEMBL2569671 | 1.00 | CNR2 (0.54) | CNR2CYP2C8CYP2D6CNR1CYP2C19 | |
| SCHEMBL16695431 | 0.81 | FFAR4 (0.45) | NOTUMKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4827644 | 0.81 | CNR2 (0.53) | CNR2CYP2C8CYP2D6CNR1CYP2C19 | |
| SCHEMBL4827642 | 0.81 | CNR2 (0.53) | CNR2CYP2C8CYP2D6CNR1CYP2C19 | |
| SCHEMBL25262222 | 0.81 | TDP1 (0.45) | KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL432319 | 0.80 | SMN1; SMN2 (0.51) | NOTUMKMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL15664724 | 0.80 | SMN1; SMN2 (0.51) | NOTUMKMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL630857 | 0.80 | SMN1; SMN2 (0.51) | NOTUMKMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL2942985 | 0.80 | SERPINE1 (0.48) | CNR2CYP2C8CYP2D6CNR1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-7408071-B2 | N-aryl pyrrolidine derivatives as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-05 | — | — | US | disclosed |
| US-7408071-B2 | N-aryl pyrrolidine derivatives as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-05 | — | — | US | disclosed |
| US-7408071-B2 | N-aryl pyrrolidine derivatives as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070232679-A1 | N-Aryl Pyrrolidine Derivatives as Beta-Secretase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070232679-A1 | N-Aryl Pyrrolidine Derivatives as Beta-Secretase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070232679-A1 | N-Aryl Pyrrolidine Derivatives as Beta-Secretase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232679-A1 | N-Aryl Pyrrolidine Derivatives as Beta-Secretase Inhibitors | BACE1, APP, PSEN1 | CNR2 1657/4885CYP2C8 3200/4885CYP2D6 1893/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CYP2C8 807/4885CYP2D6 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.